Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease

Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease

PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal Clinical Trial for FDA Market Authorization

PhotoPharmics, an innovator in Parkinson’s disease research and treatment, today announced the successful first close of a $16 million investment round. The investment round, led by Kickstart Fund, a venture capital firm based in Salt Lake City, marks a significant milestone in PhotoPharmics’ mission to revolutionize Parkinson’s disease treatment.

The primary purpose of this investment round is to fund a pivotal clinical trial aimed at obtaining FDA market authorization for Celeste PhotoPharmics’ FDA breakthrough therapeutic device for Parkinson’s disease. In research to this point, the innovative therapy has shown remarkable potential in improving overall function and quality of life for people with Parkinson’s disease.

Kent Savage, CEO of PhotoPharmics, expressed his gratitude for the support of investors, stating, “This investment is a pivotal moment in our journey to transform the treatment landscape for Parkinson’s disease. With this funding, we are positioned to advance our research and bring hope to the millions of individuals living with Parkinson’s.”

Kickstart’s expertise in supporting innovative ventures played a key role in leading this investment round. Their commitment to PhotoPharmics reflects their confidence in the potential of Celeste.

The Light for PD trial meets rigorous FDA and world-wide standards and will assess the safety and efficacy of Celeste, a non-invasive treatment for Parkinson’s disease. Celest is designed to improve both motor and non-motor function, offering a comprehensive non-pharmaceutical approach to Parkinson’s care.

Trial Description
—————
The Light for PD trial will be a landmark study in the field of Parkinson’s disease treatment. This pivotal trial is designed to demonstrate Celeste’s potential to significantly enhance the lives of patients by targeting a range of symptoms, including motor dysfunction, sleep disturbances, fatigue, mood fluctuations, cognitive impairments, reduced activity levels, and disruptions in circadian rhythm.

What sets this trial apart is its inclusive and accessible virtual design. Participants will have the opportunity to engage from the comfort of their own homes, eliminating geographical barriers and ensuring a diverse and representative population. Celeste is used passively in the home and clinical visits will be conducted via Zoom videoconferencing.

The investor’s commitments underscore the growing recognition of the potential of Celeste to improve the lives of Parkinson’s patients and reaffirms PhotoPharmics’ commitment to pushing the boundaries of innovation in the field of neurodegenerative diseases.

About PhotoPharmics
—————
PhotoPharmics is a privately held, clinical-stage medical device company developing next-generation treatments for treating neurodegenerative disorders through the eyes. Company founders have 30+ years of research and experience in this field. They previously developed specialized light solutions now widely used to regulate circadian rhythms in seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007).

Drawing from research and recent trials, PhotoPharmics is developing applications of specialized phototherapy across several neurodegenerative diseases. The company aims to make a clinically meaningful difference in patients’ lives by delivering safe and effective non-invasive treatments. Investor inquiries are welcomed. Learn more at www.photopharmics.com.
###

Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress

Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress

PhotoPharmics to showcase groundbreaking research at the prestigious international event July 5-7, 2023

PhotoPharmics, a leading innovator in Parkinson’s disease, today announced that it will be presenting its pivotal trial design at the World Parkinson Congress July 5th to 7th, 2023 in Barcelona. Aimed at advancing the company’s FDA breakthrough therapy (https://photopharmics.com/fda-grants-breakthrough-designation-for-non-invasive-phototherapy-device-in-parkinsons-disease/) one step closer to market, this at-home, remote randomized clinical trial further solidifies PhotoPharmics’ position as a pioneer in treating Parkinson’s disease.

The World Parkinson Congress is as an exceptional platform where renowned scientists, clinical researchers, healthcare professionals, and individuals affected by Parkinson’s disease convene, exchange knowledge, and engage in cutting-edge scientific discourse. This international gathering facilitates discussions surrounding the latest discoveries, medical breakthroughs, and comprehensive care practices related to Parkinson’s disease.

“We’re delighted with the opportunity to showcase our pivotal trial design at the World Parkinson Congress,” said Kent Savage, CEO of PhotoPharmics. “Presenting here allows our team to collaborate with leading researchers and potential trial participants in advancing our pivotal trial and eventual FDA clearance.”

The focal point of the company’s poster presentation at the Congress will be its highly anticipated, entirely remote, FDA pivotal trial for Celeste, an FDA breakthrough non-invasive treatment for Parkinson’s disease. Through previous trials, Celeste has demonstrated the potential to improve Parkinson’s symptoms beyond the current standards of medical care, setting it apart from existing therapies (see https://photopharmics.com/pivotal-parkinsons-disease-clinical-trial-results-released-at-the-international-movement-disorders-society-congress/).

Savage further elaborated on the groundbreaking potential of Celeste, remarking, “From our earlier trials, we’ve seen Celeste deliver safe improvements in sleep, daytime sleepiness, fatigue, cognition, motor symptoms, and psychological health.”

The Celeste Light 4 PD trial represents a significant advancement in the accessibility of FDA breakthrough therapies. Employing a fully virtual approach, the trial allows participants to engage in the comfort of their homes. All visits will be conducted via Zoom videoconferencing, and participants will receive the Celeste device through convenient shipment.

“Our trial design improves access and reduces costs by allowing those with Parkinson’s who find it difficult to visit a clinic or who live in remote areas to participate in an FDA quality trial,” Savage emphasized. “This makes it possible for so many to be involved in what could be the first major breakthrough in Parkinson’s in decades.”

If successful, Celeste will become the first treatment to alleviate several non-motor symptoms, including sleep, fatigue, mood, cognitive impairments, reduced activity levels, and disrupted circadian rhythm. These symptoms are often as debilitating as the motor problems associated with Parkinson’s disease. Moreover, Celeste aims to improve overall motor symptoms without the burden of adverse side effects and may potentially delay the need for additional dopaminergic medications.

The innovative potential of Celeste lies in its mechanism of action. While Parkinson’s disease primarily affects the motor center of the brain, recent evidence reveals deterioration in the ganglion layer of the retina, responsible for signaling to the brain that affects many non-motor symptoms as well as most physiological behavior. Celeste’s phototherapy stimulates the affected retinal neurons, similar to the stimulation of motor neurons by traditional Parkinson’s medications. Promising results from a double-blind trial indicate that the combination of Celeste with current therapies may improve upon the current standard of care for Parkinson’s disease.

PhotoPharmics’ participation at the World Parkinson Congress and its commitment to advancing Parkinson’s disease treatment underscores the company’s dedication to scientific progress and improving patients’ lives. By embracing virtual trial methodologies and exploring the intricate mechanisms of the disease, PhotoPharmics is at the forefront of transformative research in Parkinson’s disease.

About PhotoPharmics
————-
PhotoPharmics is a leading medical device company focused on revolutionizing the treatment landscape for Parkinson’s disease. With a strong commitment to scientific research and innovation, the company aims to develop breakthrough therapies that address the complex and diverse challenges faced by individuals with Parkinson’s. Led by CEO Kent Savage, PhotoPharmics leverages cutting-edge technology and a deep understanding of the disease to drive advancements in non-invasive treatments.

Through its groundbreaking Celeste Light for PD trial, PhotoPharmics is pioneering a virtual trial design that ensures inclusivity and accessibility for participants. By eliminating geographical barriers and offering remote participation, the company is expanding opportunities for individuals to contribute to the advancement of Parkinson’s research.

PhotoPharmics’ participation at the World Parkinson Congress represents a pivotal moment in the company’s journey, showcasing its dedication to collaboration, knowledge exchange, and the pursuit of improved patient outcomes. With a vision to transform the lives of individuals living with Parkinson’s, PhotoPharmics continues to push the boundaries of innovation and remains committed to bringing new hope to the Parkinson’s community.

###

PhotoPharmics to Present at MTI All Stars Investor Showcase

PhotoPharmics to Present at MTI All Stars Investor Showcase

DeviceTalks in Boston on May 10-11 to feature pitches from PhotoPharmics and other leading startups

PhotoPharmics today announced CEO Kent Savage has been invited to present at the inaugural MTI All Stars Investor Showcase at Device Talks Boston on May 10 and 11. The event will feature pitches from 22 MedTech Innovator alumni companies, offering essential insights for investors, engineers, executives, and other medical device industry professionals.

According to event organizers, DeviceTalks Boston is designed to provide valuable insights in easy-to-identify tracks, for funding and leading start-ups, engineering and developing new prototypes and devices, manufacturing medical devices with new materials and technologies, and bringing new products to market through regulatory, reimbursement, and commercial challenges.

The conference will feature keynote interviews, panel discussions, and presentations from leading companies in neurology, orthopedics, cardiovascular, image-guided devices, surgical robotics, and more. Attendees will have the opportunity to connect with proven leaders in the industry and hear about the latest innovations and trends.

“We’re pleased to present the exciting developments at PhotoPharmics,” said Kent Savage, CEO of PhotoPharmics. “It’s wonderful to be recognized for our innovative therapeutic device for people with Parkinson’s disease and the breakthrough it represents.”

Savage will speak as part of the MedTech Innovator All-Stars Presentations section of the event on May 11, 2023 at 11:15 AM.

“DeviceTalks Boston provides the perfect opportunity for networking with investors, top experts in medical device design, manufacturing, and sales,” said Savage. “We expect a critical mass of resources for companies like ours seeking insights and help on developing intricate and critical technologies.”

About MedTech Innovator
————-
The MedTech Innovator program is the world’s largest life sciences accelerator, with a mission to accelerate the growth of companies that are transforming the healthcare system. Participants benefit from broad exposure and mentorship from leading players in the medtech industry.

About PhotoPharmics
————-
PhotoPharmics is a privately held, clinical-stage medical device company developing next-generation treatments for treating neurodegenerative disorders through the eyes. Company founders have 30+ years of research and experience in this field. They previously developed specialized light solutions now widely used to regulate circadian rhythms in seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007).

Drawing from research and recent trials, PhotoPharmics is developing applications of specialized light across several neurodegenerative diseases. The company aims to make a clinically meaningful difference in patients’ lives by delivering safe and effective non-invasive treatments. Investor inquiries are welcomed. Learn more at www.photopharmics.com.

PR#10101

“Breaking Through the FDA” (Biosphere, 2021)

Innovative medical devices and diagnostics can get to patients and providers sooner under the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Program. The program provides a special regulatory Breakthrough Device Designation for medical products that have the potential to more effectively treat or diagnose serious or life-threatening conditions. See the full article on page 19 >

PhotoPharmics brings renowned experts in Parkinson’s disease and other neurodegenerative diseases to advisory board

View full press release on Businesswire.​

PhotoPharmics brings renowned experts in Parkinson’s disease and other neurodegenerative diseases to advisory board

Breakthrough device innovator will leverage the expertise of leading authorities to bolster the company’s future success in treating major unmet needs of Parkinson’s disease and beyond

Clinical-stage medical device maker PhotoPharmics today announced a Clinical & Scientific Advisory board (CSAB) comprised of six leading experts in Parkinson’s disease (PD) and other neurodegenerative diseases. The board’s aim is to provide clinical and scientific advice and direction to support the PhotoPharmics mission to “Improve the lives of people who suffer from neurodegenerative diseases.”

The board will be chaired by C. Warren Olanow, MD, a leading researcher, clinician, and influencer in developing solutions for PD and other neurodegenerative diseases, advisor to dozens of life science companies and organizations, including the Michael J Fox Foundation and National Space Board Research Institute, and the recipient of a lifetime achievement award from the International Parkinson and Movement Disorder Society.

“We are extremely pleased that Dr. Olanow has agreed to chair our Advisory Board,” said Kent Savage, CEO of PhotoPharmics. “Add to his impressive background the expertise of each of our other experts, and we are well organized to move our breakthrough platform technology through trials and into the hands of people with Parkinson’s and other neurodegenerative diseases.”

Joining Dr. Olanow on this board will be:

  • Ray Chaudhuri, MD, a world leading authority on non-motor symptoms of Parkinson’s disease, professor of neurology/movement disorders at King’s College London, author of hundreds of papers in this field, and co-editor of five books on PD.
  • Rajesh Pahwa, MD, Chief of the Parkinson’s and Movement Disorder Division and Director of Parkinson Foundation Center of Excellence at the University of Kansas Medical Center, author of more than 200 peer-reviewed articles, and instrumental in over 100 clinical trials related to PD and other movement disorders.
  • Joohi Jimenez-Shahed, MD, Medical Director of Movement Disorders Neuromodulation at Mount Sinai Hospital, principal investigator for several related clinical trials, widely published, and an emerging expert in intraoperative neurophysiology for patients undergoing deep brain stimulation (DBS) and the application of wearables and digital health technologies in PD.
  • Dan Claassen, MD, MS, Chief of Behavioral and Cognitive Neurology at Vanderbilt University, specializes in the diagnosis and treatment of neurodegenerative disorders characterized by disruptions to cognition, behavior, and movement—particularly in PD, Huntington’s, and atypical PD.
  • Amy Amara, MD, PhD, leads research efforts around movement disorders neurology and sleep at the University of Alabama at Birmingham, specializes in studies sleep disorders in PD, the influence of non-pharmacologic interventions such as exercise on sleep disorders, cognition, and other non-motor symptoms, with deep research in biomarkers in PD and interventions to improve safety in patients.

“As an emerging leader in non-invasive specialized light therapy for neurodegenerative diseases, PhotoPharmics will benefit from the advice and insight of this world-class advisory board,” said Karl Kieburtz, MD, Chief Medical Officer of PhotoPharmics. “The board will be extraordinarily valuable as we continue our clinical investigations and prepare to commercialize our therapeutic solutions.”

The board will meet regularly to advise on key strategic decisions, review emerging research, and support the company’s scientific, clinical and commercialization efforts.

About PhotoPharmics

PhotoPharmics is a privately held, clinical-stage medical device company developing next-generation treatments for treating neurodegenerative disorders through the eyes. Company founders have 30+ years of research and experience in this field. They previously developed specialized light solutions now widely used to regulate circadian rhythms in seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007).

Drawing from research and recent trials, PhotoPharmics is developing applications of specialized light across several neurodegenerative diseases. The company aims to make a clinically meaningful difference in patients’ lives by delivering safe and effective non-invasive treatments. Investor inquiries are welcomed. Learn more at www.photopharmics.com.

PR8101

###